Page last updated: 2024-10-24

caffeine and Schizophrenia

caffeine has been researched along with Schizophrenia in 67 studies

Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.

Research Excerpts

ExcerptRelevanceReference
"Clozapine is an atypical antipsychotic drug and displays efficacy in 30% to 60% of patients with schizophrenia who do not respond to traditional antipsychotics."9.09CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. ( Afra, P; Albers, LJ; Collins, EJ; Kalow, W; Kennedy, JL; Ozdemir, V; Posner, P; Reist, C; Roy, R; Tang, BK; Walkes, W, 2001)
"Cerebral blood flow (CBF) measurements and mental status examinations were performed before and 30 min after oral administration of 250 mg of caffeine or a placebo given under double-blind conditions, in two groups of patients with schizophrenia."9.06Caffeine-induced cerebral blood flow changes in schizophrenia. ( Mathew, RJ; Tant, S; Wilson, WH, 1986)
"There are numerous reports of increased use of both caffeine and nicotine in schizophrenia."8.84Use of caffeine and nicotine in people with schizophrenia. ( Gandhi, KK; Williams, JM, 2008)
"Although the database is small and not completely consistent, it appears that patients with schizophrenia have high caffeine intakes."8.80Caffeine and schizophrenia. ( Holtzman, S; Hughes, JR; McHugh, P, 1998)
"Our study is the first study in the literature that examines the relationship between caffeine and cigarette intake and SANS and SAPS scales in patients with schizophrenia."8.31Is there a Relationship Between Caffeine Intake and Smoking and Positive and Negative Symptom Severity in Schizophrenia? ( Baltaci, E; Egeli, A; Hakyemez Geylani, G; Han Almis, B; Tekin, A, 2023)
"This study further explores the association between schizophrenia and caffeine use by combining two prior published Spanish samples (250 schizophrenia outpatients and 290 controls from the general population) with two Spanish long-term inpatient samples from the same hospital (145 with schizophrenia and 64 with other severe mental illnesses)."7.81Caffeine consumption in a long-term psychiatric hospital: Tobacco smoking may explain in large part the apparent association between schizophrenia and caffeine use. ( Armas Barbazán, C; Arrojo-Romero, M; de Leon, J; Diaz, FJ; Gurpegui, M; Jurado, D; López-Moriñigo, JD; Martínez-Ortega, JM; Ramos-Ríos, R, 2015)
"Fixed oral doses of clozapine produce up to 45-fold interindividual variability among its serum levels in patients with treatment-resistant schizophrenia."7.79Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. ( Jacob, KS; Jacob, M; Kuruvilla, A; Poonkuzhali, B; Rajkumar, AP, 2013)
"Previous studies of high dietary caffeine intake in individuals with schizophrenia have not demonstrated biological evidence of higher intake or controlled smoking behavior."7.76Higher serum caffeine in smokers with schizophrenia compared to smoking controls. ( Benowitz, NL; Galazyn, M; Gandhi, KK; Menza, M; Williams, JM, 2010)
"Cigarette smoking and caffeine use are established and problematic drug-use behaviors in people with schizophrenia."7.75Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia. ( Adolfo, AB; AhnAllen, CG; Tidey, JW, 2009)
" The aim of this study was to evaluate the effect of subchronic caffeine treatment on MK-801-induced hyperlocomotion, ataxia and cognitive deficits, as well as amphetamine-induced hyperlocomotion in mice."7.73Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice. ( Dall'Igna, OP; de Oliveira, RV; Lara, DR; Neto, PF; Santos Gomes, MW; Schuh, JF; Souza, DO; Tort, AB, 2005)
"According to the literature, there is an association between schizophrenia and caffeine consumption, but it is not clear whether schizophrenia is associated with either higher prevalence of daily caffeine intake or the amount consumed."7.73Fewer but heavier caffeine consumers in schizophrenia: a case-control study. ( Aguilar, MC; de Leon, J; Diaz, FJ; Gurpegui, M; Jurado, D; Martínez-Ortega, JM; Quintana, HM, 2006)
"Community-dwelling schizophrenia patients consume significantly more caffeine and nicotine than US population comparisons."7.73Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. ( Brar, JS; Ganguli, R; Strassnig, M, 2006)
"Several studies suggest that caffeine intake is high in patients with schizophrenia and a few of them suggest that caffeine may contribute to schizophrenia symptomatology."7.72Caffeine intake in outpatients with schizophrenia. ( Aguilar, MC; de Leon, J; Diaz, FJ; Gurpegui, M; Martínez-Ortega, JM, 2004)
"Adenosine A (2A) receptors have been implicated in the pathophysiology of schizophrenia by clinical, anatomical, biochemical and genetic studies."7.72Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. ( Brenner, M; Danielczyk, W; Deckert, J; Durany, N; Jellinger, K; Paulus, W; Ransmayr, G; Riederer, P; Tatschner, T; Zöchling, R, 2003)
"In a previous paper, I have proposed that the deficiency of an endogenous caffeine-like substance is the underlying pathogenic mechanism in schizophrenia (1)."7.68Exploring the role of an endogenous caffeine-like substance in the pathogenesis of schizophrenia. ( Missak, SS, 1991)
"Schizophrenia is a common psychiatric disorder which affects approximately 1% of the population worldwide."6.72Caffeine consumption and schizophrenia: A highlight on adenosine receptor-independent mechanisms. ( Huang, L; Sperlágh, B, 2021)
"Caffeine, 10 mg/kg, was administered to 13 schizophrenic patients in a double-blind placebo-controlled study of its behavioral effects."6.67Effects of the acute administration of caffeine in patients with schizophrenia. ( Hommer, D; Kelsoe, J; Lucas, PB; Pato, C; Pickar, D; Rapaport, M, 1990)
"As caffeine has been shown to selectively increase dopaminergic neurotransmission in mesocortical neurons, further study utilizing dopamine agonists during SPEM in schizophrenic patients is warranted."6.66Smooth pursuit eye movements in schizophrenia: effects of neuroleptic treatment and caffeine. ( Clem, T; Hommer, DW; Litman, RE; Pato, CN; Pickar, D; Rapaport, MH, 1989)
"Individuals with schizophrenia use twice as much caffeine on average when compared to healthy controls."5.51Alteration of Resting Electroencephalography by Acute Caffeine Consumption in Early Phase Psychosis. ( Anderson, TJ; Fisher, DJ; McKearney, KJ; N Bissonnette, J; Tibbo, PG, 2022)
"The high prevalence of substance use, e."5.29Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia. ( Deviney, S; Hamera, E; Schneider, JK, 1995)
"Clozapine is an effective atypical antipsychotic drug applied in the treatment of resistant schizophrenia."5.10CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. ( Doude van Troostwijk, LJ; Guchelaar, HJ; Koopmans, RP; Vermeulen, HD, 2003)
"Clozapine is an atypical antipsychotic drug and displays efficacy in 30% to 60% of patients with schizophrenia who do not respond to traditional antipsychotics."5.09CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia. ( Afra, P; Albers, LJ; Collins, EJ; Kalow, W; Kennedy, JL; Ozdemir, V; Posner, P; Reist, C; Roy, R; Tang, BK; Walkes, W, 2001)
"Cerebral blood flow (CBF) measurements and mental status examinations were performed before and 30 min after oral administration of 250 mg of caffeine or a placebo given under double-blind conditions, in two groups of patients with schizophrenia."5.06Caffeine-induced cerebral blood flow changes in schizophrenia. ( Mathew, RJ; Tant, S; Wilson, WH, 1986)
"There are numerous reports of increased use of both caffeine and nicotine in schizophrenia."4.84Use of caffeine and nicotine in people with schizophrenia. ( Gandhi, KK; Williams, JM, 2008)
"Although the database is small and not completely consistent, it appears that patients with schizophrenia have high caffeine intakes."4.80Caffeine and schizophrenia. ( Holtzman, S; Hughes, JR; McHugh, P, 1998)
"Our study is the first study in the literature that examines the relationship between caffeine and cigarette intake and SANS and SAPS scales in patients with schizophrenia."4.31Is there a Relationship Between Caffeine Intake and Smoking and Positive and Negative Symptom Severity in Schizophrenia? ( Baltaci, E; Egeli, A; Hakyemez Geylani, G; Han Almis, B; Tekin, A, 2023)
"A 34 year old male with a history of chronic schizophrenia, who had been managed stably on 400 mg Clozapine for the previous 5 years, changed his dietary behaviour and began consuming caffeine-containing energy drinks over the course of 3 weeks."4.02Caffeine-clozapine interaction associated with severe toxicity and multiorgan system failure: a case report. ( Peisah, C; Yartsev, A, 2021)
"Caffeine and nicotine are widely used by schizophrenia patients and may worsen psychosis and affect antipsychotic therapies."3.88Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance. ( Avvisati, L; Buonaguro, EF; de Bartolomeis, A; Iasevoli, F; Latte, G; Marmo, F; Tomasetti, C, 2018)
"This study further explores the association between schizophrenia and caffeine use by combining two prior published Spanish samples (250 schizophrenia outpatients and 290 controls from the general population) with two Spanish long-term inpatient samples from the same hospital (145 with schizophrenia and 64 with other severe mental illnesses)."3.81Caffeine consumption in a long-term psychiatric hospital: Tobacco smoking may explain in large part the apparent association between schizophrenia and caffeine use. ( Armas Barbazán, C; Arrojo-Romero, M; de Leon, J; Diaz, FJ; Gurpegui, M; Jurado, D; López-Moriñigo, JD; Martínez-Ortega, JM; Ramos-Ríos, R, 2015)
"Nurses in Korea should play an active role in tobacco control for patients with schizophrenia by providing cessation counseling and educating the effect of caffeine use on cigarette consumption, while tailoring the service to gender differences found in this study."3.79Smoking among individuals with schizophrenia in Korea: gender differences. ( Chung, S; Jung, AJ; Kalman, D; Kim, SS; Park, JI; Ziedonis, DM, 2013)
"Fixed oral doses of clozapine produce up to 45-fold interindividual variability among its serum levels in patients with treatment-resistant schizophrenia."3.79Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. ( Jacob, KS; Jacob, M; Kuruvilla, A; Poonkuzhali, B; Rajkumar, AP, 2013)
"Previous studies of high dietary caffeine intake in individuals with schizophrenia have not demonstrated biological evidence of higher intake or controlled smoking behavior."3.76Higher serum caffeine in smokers with schizophrenia compared to smoking controls. ( Benowitz, NL; Galazyn, M; Gandhi, KK; Menza, M; Williams, JM, 2010)
"Cigarette smoking and caffeine use are established and problematic drug-use behaviors in people with schizophrenia."3.75Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia. ( Adolfo, AB; AhnAllen, CG; Tidey, JW, 2009)
"According to the literature, there is an association between schizophrenia and caffeine consumption, but it is not clear whether schizophrenia is associated with either higher prevalence of daily caffeine intake or the amount consumed."3.73Fewer but heavier caffeine consumers in schizophrenia: a case-control study. ( Aguilar, MC; de Leon, J; Diaz, FJ; Gurpegui, M; Jurado, D; Martínez-Ortega, JM; Quintana, HM, 2006)
" The aim of this study was to evaluate the effect of subchronic caffeine treatment on MK-801-induced hyperlocomotion, ataxia and cognitive deficits, as well as amphetamine-induced hyperlocomotion in mice."3.73Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice. ( Dall'Igna, OP; de Oliveira, RV; Lara, DR; Neto, PF; Santos Gomes, MW; Schuh, JF; Souza, DO; Tort, AB, 2005)
"Community-dwelling schizophrenia patients consume significantly more caffeine and nicotine than US population comparisons."3.73Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. ( Brar, JS; Ganguli, R; Strassnig, M, 2006)
"Adenosine A (2A) receptors have been implicated in the pathophysiology of schizophrenia by clinical, anatomical, biochemical and genetic studies."3.72Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. ( Brenner, M; Danielczyk, W; Deckert, J; Durany, N; Jellinger, K; Paulus, W; Ransmayr, G; Riederer, P; Tatschner, T; Zöchling, R, 2003)
"Several studies suggest that caffeine intake is high in patients with schizophrenia and a few of them suggest that caffeine may contribute to schizophrenia symptomatology."3.72Caffeine intake in outpatients with schizophrenia. ( Aguilar, MC; de Leon, J; Diaz, FJ; Gurpegui, M; Martínez-Ortega, JM, 2004)
"Our data suggest that at least one drug commonly used to treat schizophrenia (haloperidol) can interfere with the vasodilatory response to NA."3.71An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response. ( Ross, BM; Seeman, M; Turenne, SD, 2001)
"This study included 204 patients treated with clozapine for schizophrenia and 192 healthy volunteers receiving a 100 mg oral test dose of caffeine."3.70Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. ( Bauer, S; Brockmöller, J; Dettling, M; Müller-Oerlinghausen, B; Roots, I; Ruschen, S; Sachse, C; Schley, J, 1999)
"In a previous paper, I have proposed that the deficiency of an endogenous caffeine-like substance is the underlying pathogenic mechanism in schizophrenia (1)."3.68Exploring the role of an endogenous caffeine-like substance in the pathogenesis of schizophrenia. ( Missak, SS, 1991)
"Schizophrenia is a common psychiatric disorder which affects approximately 1% of the population worldwide."2.72Caffeine consumption and schizophrenia: A highlight on adenosine receptor-independent mechanisms. ( Huang, L; Sperlágh, B, 2021)
" Seventeen psychiatric patients (9 men and 8 women) were orally administered olanzapine, at a mean +/- standard deviation (SD) dosage of 10 mg/d for all smokers (n = 8) and 7."2.71Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. ( Benítez, J; Carrillo, JA; Gervasini, G; Herráiz, AG; Ramos, SI; Vizcaíno, S, 2003)
"Caffeine, 10 mg/kg, was administered to 13 schizophrenic patients in a double-blind placebo-controlled study of its behavioral effects."2.67Effects of the acute administration of caffeine in patients with schizophrenia. ( Hommer, D; Kelsoe, J; Lucas, PB; Pato, C; Pickar, D; Rapaport, M, 1990)
"As caffeine has been shown to selectively increase dopaminergic neurotransmission in mesocortical neurons, further study utilizing dopamine agonists during SPEM in schizophrenic patients is warranted."2.66Smooth pursuit eye movements in schizophrenia: effects of neuroleptic treatment and caffeine. ( Clem, T; Hommer, DW; Litman, RE; Pato, CN; Pickar, D; Rapaport, MH, 1989)
"Caffeine is an easily available drug which is generally regarded as being safe."1.40Caffeine intoxication successfully treated by hemoperfusion and hemodialysis. ( Fukasawa, H; Furuya, R; Ishigaki, S; Kinoshita-Katahashi, N; Kumagai, H; Yasuda, H, 2014)
"Treatment with risperidone for 4 weeks did not increase daily cigarette consumption or plasma levels of cotinine and caffeine."1.35Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study. ( Hori, H; Kakihara, S; Nakamura, J; Sugita, A; Ueda, N; Umene-Nakano, W; Yoshimura, R, 2008)
"The influence of temperament on substance abuse in schizophrenia is poorly understood, whereas it is known to play an important role in other clinical populations."1.30Temperament and substance abuse in schizophrenia: is there a relationship? ( Mulder, RT; Sellman, JD; Van Ammers, EC, 1997)
"The high prevalence of substance use, e."1.29Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia. ( Deviney, S; Hamera, E; Schneider, JK, 1995)

Research

Studies (67)

TimeframeStudies, this research(%)All Research%
pre-199017 (25.37)18.7374
1990's15 (22.39)18.2507
2000's15 (22.39)29.6817
2010's12 (17.91)24.3611
2020's8 (11.94)2.80

Authors

AuthorsStudies
Huang, L1
Sperlágh, B1
N Bissonnette, J1
Anderson, TJ1
McKearney, KJ1
Tibbo, PG1
Fisher, DJ1
Rosen, RL2
Ramasubramani, RS2
Benowitz, NL3
Gandhi, KK4
Williams, JM4
Szoke, A1
Richard, JR1
Fond, G1
Misdrahi, D1
Lajnef, M1
Aouizerate, B1
Boyer, L1
Berna, F1
Capdevielle, D1
André, M1
Chereau, I1
Clauss-Kobayashi, J1
Coulon, N1
Dubertret, C1
Leignier, S1
Llorca, PM1
Mallet, J1
Passerieux, C1
Rey, R1
Schorr, B1
Urbach, M1
Leboyer, M1
Pignon, B1
Schürhoff, F1
Han Almis, B1
Tekin, A1
Hakyemez Geylani, G1
Baltaci, E1
Egeli, A1
Ramos, AC1
de Mattos Hungria, F1
Camerini, BA1
Suiama, MA1
Calzavara, MB1
Horvath, G1
Adam, G1
Tuboly, G1
Kekesi, G1
Büki, A1
Ducza, E1
Szűcs, E1
Benyhe, S1
Benedek, G1
Yartsev, A1
Peisah, C1
de Bartolomeis, A1
Iasevoli, F1
Marmo, F1
Buonaguro, EF1
Avvisati, L1
Latte, G1
Tomasetti, C1
Topyurek, M1
Tibbo, P1
Núñez, C2
Stephan-Otto, C2
Good, K1
Thoma, P1
Daum, I1
Kim, SS1
Chung, S1
Park, JI1
Jung, AJ1
Kalman, D1
Ziedonis, DM1
Peng, PJ1
Chiang, KT1
Liang, CS1
Ishigaki, S1
Fukasawa, H1
Kinoshita-Katahashi, N1
Yasuda, H1
Kumagai, H1
Furuya, R1
Arrojo-Romero, M1
Armas Barbazán, C1
López-Moriñigo, JD1
Ramos-Ríos, R1
Gurpegui, M3
Martínez-Ortega, JM3
Jurado, D2
Diaz, FJ3
de Leon, J3
Cuevas-Esteban, J1
Maria Haro, J1
Huerta-Ramos, E1
Ochoa, S1
Usall, J1
Brébion, G1
Adolfo, AB1
AhnAllen, CG1
Tidey, JW1
Menza, M1
Galazyn, M1
BARUK, H1
RACINE, M1
Tibrewal, P1
Dhillon, R1
Yoshimura, R3
Nakamura, J3
Rajkumar, AP1
Poonkuzhali, B1
Kuruvilla, A1
Jacob, M1
Jacob, KS1
Deckert, J1
Brenner, M1
Durany, N1
Zöchling, R1
Paulus, W1
Ransmayr, G1
Tatschner, T1
Danielczyk, W1
Jellinger, K1
Riederer, P1
Carrillo, JA2
Herráiz, AG2
Ramos, SI2
Gervasini, G1
Vizcaíno, S1
Benítez, J2
BRUCK, D1
ABELY, P1
RICHARDEAU, N1
DEDIEU-ANGLADE, G1
BENOIT, JC1
LYNN, R1
GUSHANSKII, EL1
PFEIFFER, CC1
GOLDSTEIN, L1
MURPHREE, HB1
SUGERMAN, AA1
BAZHIN, EF1
Doude van Troostwijk, LJ1
Koopmans, RP1
Vermeulen, HD1
Guchelaar, HJ1
Bozikas, VP1
Papakosta, M1
Niopas, I1
Karavatos, A1
Mirtsou-Fidani, V1
Kakihara, S2
Shinkai, K1
Matsumoto, C1
Goto, M1
Kaji, K1
Yamada, Y1
Ueda, N2
Ohmori, O1
de Oliveira, RV1
Dall'Igna, OP1
Tort, AB1
Schuh, JF1
Neto, PF1
Santos Gomes, MW1
Souza, DO1
Lara, DR1
Aguilar, MC2
Quintana, HM1
Strassnig, M1
Brar, JS1
Ganguli, R1
Brown, GG1
Eyler, LT1
Umene-Nakano, W1
Sugita, A1
Hori, H1
Hamera, E1
Schneider, JK1
Deviney, S1
Marcus, P1
Snyder, R1
Zaretsky, A1
Rector, NA1
Seeman, MV1
Fornazzari, X1
Vainer, JL1
Chouinard, G1
Mayo, KM1
Falkowski, W1
Jones, CA1
Donnelly, CL1
McEvoy, JP1
Wilson, WH2
Narasimhachari, N1
Van Ammers, EC1
Sellman, JD1
Mulder, RT1
Hughes, JR1
McHugh, P1
Holtzman, S1
Dixon, DA1
Fenix, LA1
Kim, DM1
Raffa, RB1
Sachse, C1
Ruschen, S1
Dettling, M1
Schley, J1
Bauer, S1
Müller-Oerlinghausen, B1
Roots, I1
Brockmöller, J1
Turenne, SD1
Seeman, M1
Ross, BM1
Ozdemir, V1
Kalow, W1
Posner, P1
Collins, EJ1
Kennedy, JL1
Tang, BK1
Albers, LJ1
Reist, C1
Roy, R1
Walkes, W1
Afra, P1
Rotrosen, J1
Miller, AD1
Mandio, D1
Traficante, LJ1
Gershon, S1
Mikkelsen, EJ1
Goff, DC1
Henderson, DC1
Amico, E1
Missak, SS1
Hyde, AP1
Lucas, PB1
Pickar, D2
Kelsoe, J1
Rapaport, M1
Pato, C1
Hommer, D1
Litman, RE1
Hommer, DW1
Clem, T1
Rapaport, MH1
Pato, CN1
Koczapski, A1
Paredes, J1
Kogan, C1
Ledwidge, B1
Higenbottam, J1
Kirubakaran, V1
Holsboer-Trachsler, E1
Buol, C1
Wiedemann, K1
Holsboer, F1
Mathew, RJ1
Tant, S1
Uhde, TW1
Bierer, LM1
Post, RM1
Arushanian, EB1
Stoliarov, GV1
Tolpyshev, BA1
Lugovskiĭ, BK1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Impact of Caffeine on Cognition in Schizophrenia[NCT02832401]24 participants (Actual)Interventional2016-09-02Completed
Clinical Trial of Dipyridamole in Schizophrenia[NCT00349973]29 participants (Actual)Interventional2001-05-31Completed
A Randomized Trial Administering Estradiol Patch vs. Placebo Patch as add-on to Antipsychotics in Female Patients Above the Age of 38 With Schizophrenia, Schizoaffective or Schizophreniform Disorder[NCT04093518]Phase 3100 participants (Anticipated)Interventional2019-12-02Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Negative Symptoms by Treatment Assignment

The Scale for the Assessment of Negative Symptoms (SANS) total score, minus the global items, inappropriate affect, poverty of content of speech, and attention items, used to measure negative symptoms. Mean SANS total score by treatment and week. SANS total score range = 0-85. Higher scores indicate more severe negative symptoms. (NCT00349973)
Timeframe: Baseline and Follow-Up

,
Interventionunits on a scale (Mean)
Baseline (Phase 1/Week 1)Follow-Up (Phase 4/Week 1)
Dipyridamole23.325.8
Olanzapine25.627.0

Change in Positive Symptoms by Treatment Assignment

"The Brief Psychiatric Rating Scale (BPRS) consists of 20 items, with 6 of these items used to assess positive symptom change. The BPRS positive symptom items are: somatic concern, conceptual disorganization, hostility, suspiciousness, hallucinatory behavior, and unusual thought content. Each scale ranges from 1=Not Present to 7=Very Severe. A higher score indicates a more severe positive symptom rating." (NCT00349973)
Timeframe: Baseline and follow-up

,
Interventionunits on a scale (Mean)
Baseline - Somatic ConcernFollow-Up - Somatic ConcernBaseline - Conceptual DisorganizationFollow-Up - Conceptual DisorganizationBaseline - HostilityFollow-Up - HostilityBaseline - SuspiciousnessFollow-Up - SuspiciousnessBaseline - HallucinationFollow-Up - HallucinationBaseline - Unusual Thought ContentFollow-Up - Unusual Thought Content
Dipyridamole2.2221.602.6672.001.2221.004.113.0002.672.6003.1112.800
Olanzapine1.4001.002.6002.001.2002.003.401.5003.802.5003.4001.500

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

The RBANS is a brief, individually administered test designed to evaluate neuropsychological status of adults, ages 20-89. The 12 subtests measure attention, language, visuospatial/constructional abilities, and immediate and delayed memory. The raw scores from the subtests are scaled together to create index scores, and these are summed for conversion to a total scale score. Higher score equals a better outcome. The total index score range for the RBANS is 40-160. (NCT00349973)
Timeframe: Baseline and Follow-Up

,
Interventionunits on a scale (Mean)
Baseline (Phase 1/Week 1)Follow-Up (Phase 3/Week 6)
Dipyridamole73.0077.40
Olanzapine59.0065.00

Reviews

7 reviews available for caffeine and Schizophrenia

ArticleYear
Caffeine consumption and schizophrenia: A highlight on adenosine receptor-independent mechanisms.
    Current opinion in pharmacology, 2021, Volume: 61

    Topics: Antipsychotic Agents; Brain-Gut Axis; Caffeine; Humans; Receptors, Purinergic P1; Schizophrenia

2021
Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings.
    Psychiatry and clinical neurosciences, 2013, Volume: 67, Issue:6

    Topics: Alcoholism; Brain; Caffeine; Central Nervous System Stimulants; Cognition; Comorbidity; Diagnosis, D

2013
Use of caffeine and nicotine in people with schizophrenia.
    Current drug abuse reviews, 2008, Volume: 1, Issue:2

    Topics: Antipsychotic Agents; Aryl Hydrocarbon Hydroxylases; Brain; Caffeine; Comorbidity; Cross-Sectional S

2008
RUSSIAN THEORY AND RESEARCH ON SCHIZOPHRENIA.
    Psychological bulletin, 1963, Volume: 60

    Topics: Amobarbital; Bromides; Caffeine; Cerebral Cortex; Chlorpromazine; Conditioning, Psychological; Convu

1963
Methodological and conceptual issues in functional magnetic resonance imaging: applications to schizophrenia research.
    Annual review of clinical psychology, 2006, Volume: 2

    Topics: Bionics; Biophysics; Brain; Caffeine; Cerebral Cortex; Forecasting; Humans; Magnetic Resonance Imagi

2006
Caffeine and schizophrenia.
    Psychiatric services (Washington, D.C.), 1998, Volume: 49, Issue:11

    Topics: Animals; Antipsychotic Agents; Caffeine; Dopamine; Drug Interactions; Humans; Rats; Schizophrenia; S

1998
Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: I. Adenosine agonists.
    The Annals of pharmacotherapy, 1999, Volume: 33, Issue:4

    Topics: Adenosine; Animals; Caffeine; Clinical Trials as Topic; Drug Interactions; Humans; Mutation; Neurotr

1999

Trials

10 trials available for caffeine and Schizophrenia

ArticleYear
Alteration of Resting Electroencephalography by Acute Caffeine Consumption in Early Phase Psychosis.
    Clinical EEG and neuroscience, 2022, Volume: 53, Issue:4

    Topics: Caffeine; Electroencephalography; Humans; Psychotic Disorders; Rest; Schizophrenia

2022
Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.
    Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:2

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Caffeine; Chromatography, High Pressure Liquid; Cytoch

2003
CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2003, Volume: 20, Issue:4-5

    Topics: Adult; Algorithms; Antipsychotic Agents; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Female; Human

2003
Caffeine: use and effects in long-stay psychiatric patients.
    The British journal of psychiatry : the journal of mental science, 1993, Volume: 162

    Topics: Adult; Aged; Anxiety Disorders; Caffeine; Depressive Disorder; Dose-Response Relationship, Drug; Dou

1993
A study of the potential confounding effects of diet, caffeine, nicotine and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia.
    Biological psychiatry, 1996, Dec-15, Volume: 40, Issue:12

    Topics: Adult; Caffeine; Central Nervous System Stimulants; Diet; Drug Interactions; GABA Modulators; Homova

1996
CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
    Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:4

    Topics: Adult; Aged; Antipsychotic Agents; Caffeine; Clozapine; Cytochrome P-450 CYP1A2; Dose-Response Relat

2001
Effects of the acute administration of caffeine in patients with schizophrenia.
    Biological psychiatry, 1990, Jul-01, Volume: 28, Issue:1

    Topics: Adolescent; Adult; Arousal; Caffeine; Female; Humans; Hydrocortisone; Male; Psychiatric Status Ratin

1990
Smooth pursuit eye movements in schizophrenia: effects of neuroleptic treatment and caffeine.
    Psychopharmacology bulletin, 1989, Volume: 25, Issue:3

    Topics: Adult; Antipsychotic Agents; Caffeine; Eye Movements; Humans; Saccades; Schizophrenia

1989
Caffeine-induced cerebral blood flow changes in schizophrenia.
    European archives of psychiatry and neurological sciences, 1986, Volume: 235, Issue:4

    Topics: Adult; Caffeine; Cerebrovascular Circulation; Female; Humans; Male; Regional Blood Flow; Schizophren

1986
Caffeine-induced escape from dexamethasone suppression.
    Archives of general psychiatry, 1985, Volume: 42, Issue:7

    Topics: Adult; Caffeine; Clinical Trials as Topic; Coffee; Depressive Disorder; Dexamethasone; Dose-Response

1985

Other Studies

50 other studies available for caffeine and Schizophrenia

ArticleYear
Caffeine levels and dietary intake in smokers with schizophrenia and bipolar disorder.
    Psychiatry research, 2023, Volume: 319

    Topics: Adult; Bipolar Disorder; Caffeine; Child; Humans; Schizophrenia; Smokers; Smoking; United States

2023
Caffeine levels and dietary intake in smokers with schizophrenia and bipolar disorder.
    Psychiatry research, 2023, Volume: 319

    Topics: Adult; Bipolar Disorder; Caffeine; Child; Humans; Schizophrenia; Smokers; Smoking; United States

2023
Caffeine levels and dietary intake in smokers with schizophrenia and bipolar disorder.
    Psychiatry research, 2023, Volume: 319

    Topics: Adult; Bipolar Disorder; Caffeine; Child; Humans; Schizophrenia; Smokers; Smoking; United States

2023
Caffeine levels and dietary intake in smokers with schizophrenia and bipolar disorder.
    Psychiatry research, 2023, Volume: 319

    Topics: Adult; Bipolar Disorder; Caffeine; Child; Humans; Schizophrenia; Smokers; Smoking; United States

2023
Clinical and pharmacological correlates of caffeine consumption in subjects with schizophrenia - Data from the FACE-SZ cohort.
    Journal of psychiatric research, 2023, Volume: 161

    Topics: Caffeine; Coffee; Humans; Schizophrenia; Smoking; Tea

2023
Is there a Relationship Between Caffeine Intake and Smoking and Positive and Negative Symptom Severity in Schizophrenia?
    Psychiatria Danubina, 2023,Spring, Volume: 35, Issue:1

    Topics: Caffeine; Humans; Psychiatric Status Rating Scales; Schizophrenia; Smoking

2023
Potential beneficial effects of caffeine administration in the neonatal period of an animal model of schizophrenia.
    Behavioural brain research, 2020, 08-05, Volume: 391

    Topics: Adenosine; Animals; Animals, Newborn; Caffeine; Disease Models, Animal; Locomotion; Male; Motor Acti

2020
Caffeine - treat or trigger? Disparate behavioral and long-term dopaminergic changes in control and schizophrenia-like Wisket rats.
    Physiology & behavior, 2021, 07-01, Volume: 236

    Topics: Animals; Brain; Caffeine; Dopamine; Humans; Prefrontal Cortex; Rats; Schizophrenia

2021
Caffeine-clozapine interaction associated with severe toxicity and multiorgan system failure: a case report.
    BMC psychiatry, 2021, 04-13, Volume: 21, Issue:1

    Topics: Adult; Antipsychotic Agents; Caffeine; Clozapine; Humans; Male; Schizophrenia

2021
Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2018, Volume: 28, Issue:4

    Topics: Animals; Brain; Caffeine; Central Nervous System Agents; Cytoskeletal Proteins; Drug Interactions; D

2018
Caffeine effects and schizophrenia: Is there a need for more research?
    Schizophrenia research, 2019, Volume: 211

    Topics: Biomedical Research; Caffeine; Central Nervous System Stimulants; Cognition; Humans; Schizophrenia;

2019
Smoking among individuals with schizophrenia in Korea: gender differences.
    Archives of psychiatric nursing, 2013, Volume: 27, Issue:5

    Topics: Caffeine; Female; Humans; Male; Middle Aged; Republic of Korea; Schizophrenia; Schizophrenic Psychol

2013
Low-dose caffeine may exacerbate psychotic symptoms in people with schizophrenia.
    The Journal of neuropsychiatry and clinical neurosciences, 2014, Apr-01, Volume: 26, Issue:2

    Topics: Caffeine; Central Nervous System Stimulants; Humans; Male; Middle Aged; Psychotic Disorders; Schizop

2014
Caffeine intoxication successfully treated by hemoperfusion and hemodialysis.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:23

    Topics: Adult; Caffeine; Central Nervous System Stimulants; Hemoperfusion; Humans; Male; Renal Dialysis; Sch

2014
Caffeine consumption in a long-term psychiatric hospital: Tobacco smoking may explain in large part the apparent association between schizophrenia and caffeine use.
    Schizophrenia research, 2015, Volume: 164, Issue:1-3

    Topics: Adult; Aged; Antipsychotic Agents; Caffeine; Central Nervous System Stimulants; Female; Hospitals, P

2015
Effects of caffeine intake and smoking on neurocognition in schizophrenia.
    Psychiatry research, 2015, Dec-30, Volume: 230, Issue:3

    Topics: Adult; Caffeine; Cognition; Female; Humans; Male; Memory, Short-Term; Middle Aged; Neuropsychologica

2015
Effects of smoking cues on caffeine urges in heavy smokers and caffeine consumers with and without schizophrenia.
    Schizophrenia research, 2009, Volume: 107, Issue:2-3

    Topics: Adult; Arousal; Beverages; Caffeine; Comorbidity; Cues; Female; Humans; Male; Middle Aged; Motivatio

2009
Higher serum caffeine in smokers with schizophrenia compared to smoking controls.
    Drug and alcohol dependence, 2010, Jul-01, Volume: 110, Issue:1-2

    Topics: Adult; Antipsychotic Agents; Caffeine; Central Nervous System Stimulants; Female; Humans; Male; Pred

2010
Trial of circulatory treatment of early early dementia with folliculin and caffeine (physiological therapeutics or shock therapeutics?).
    Annales medico-psychologiques, 1946, Volume: 104

    Topics: Caffeine; Estrogens; Mental Disorders; Psychotic Disorders; Schizophrenia

1946
Caffeine induced psychotic exacerbation.
    The Australian and New Zealand journal of psychiatry, 2011, Volume: 45, Issue:2

    Topics: Caffeine; Humans; Male; Middle Aged; Recurrence; Schizophrenia

2011
[Effects of smoking and caffeine on pharmacological treatment for patients with schizophrenia and depression].
    Nihon Arukoru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence, 2011, Volume: 46, Issue:6

    Topics: Caffeine; Depression; Drug Interactions; Fluvoxamine; Humans; Risperidone; Schizophrenia; Smoking

2011
Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia.
    International clinical psychopharmacology, 2013, Volume: 28, Issue:1

    Topics: Administration, Oral; Adult; Anticonvulsants; Antipsychotic Agents; Caffeine; Case-Control Studies;

2013
Up-regulation of striatal adenosine A(2A) receptors in schizophrenia.
    Neuroreport, 2003, Mar-03, Volume: 14, Issue:3

    Topics: Adenosine; Aged; Aged, 80 and over; Antipsychotic Agents; Cadaver; Caffeine; Control Groups; Corpus

2003
[Therapy of schizophrenia].
    Hippokrates, 1954, Jul-31, Volume: 25, Issue:14

    Topics: Caffeine; Humans; Procaine; Schizophrenia

1954
[Cutaneo-abdominal reflexes in conflict syndromes; caffeine, acecoline, prostigmine & adrenalin control tests; probable anticataionic role of adrenalin in the human].
    Annales medico-psychologiques, 1959, Volume: 117, Issue:3

    Topics: Caffeine; Epinephrine; Humans; Neostigmine; Probability; Schizophrenia; Syndrome

1959
[DYNAMICS OF SUBORDINATION AND ADAPTATION IN PATIENTS WITH THE CATATONIC FORM OF SCHIZOPHRENIA WITH CHRONIC UNFAVORABLE DEVELOPMENT].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1963, Volume: 63

    Topics: Acclimatization; Adaptation, Physiological; Caffeine; Catatonia; Central Nervous System; Chlorpromaz

1963
TIME-SERIES, FREQUENCY ANALYSIS, AND ELECTROGENESIS OF THE EEGS OF NORMALS AND PSYCHOTICS BEFORE AND AFTER DRUGS.
    The American journal of psychiatry, 1965, Volume: 121

    Topics: Amphetamine; Antidepressive Agents; Barbiturates; Biomedical Research; Caffeine; Central Nervous Sys

1965
[APROPOS OF THE USE OF THE AMYTAL-CAFFEINE DISINHIBITION IN CHRONIC SCHIZOPHRENIA IN PSYCHOPATHOLOGICAL STUDY AND PROGNOSTIC EVALUATION OF THERAPY].
    Voprosy psikhiatrii i nevropatologii; sbornik trudov, 1964, Volume: 10

    Topics: Amobarbital; Caffeine; Humans; Mental Disorders; Prognosis; Psychopathology; Schizophrenia

1964
Smoking impact on CYP1A2 activity in a group of patients with schizophrenia.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2004, Volume: 14, Issue:1

    Topics: Adult; Aged; Antipsychotic Agents; Caffeine; Chi-Square Distribution; Cytochrome P-450 CYP1A2; Enzym

2004
Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
    International clinical psychopharmacology, 2005, Volume: 20, Issue:2

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Caffeine; Catecholamines; Cen

2005
Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice.
    Behavioural pharmacology, 2005, Volume: 16, Issue:2

    Topics: Adenosine; Amphetamine; Animals; Ataxia; Caffeine; Central Nervous System Stimulants; Cognition; Dis

2005
Caffeine intake in outpatients with schizophrenia.
    Schizophrenia bulletin, 2004, Volume: 30, Issue:4

    Topics: Antipsychotic Agents; Caffeine; Central Nervous System Stimulants; Drinking Behavior; Drug Interacti

2004
Fewer but heavier caffeine consumers in schizophrenia: a case-control study.
    Schizophrenia research, 2006, Volume: 86, Issue:1-3

    Topics: Adolescent; Adult; Age Factors; Aged; Alcohol Drinking; Caffeine; Case-Control Studies; Central Nerv

2006
Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia.
    Schizophrenia research, 2006, Volume: 86, Issue:1-3

    Topics: Adult; Body Mass Index; Caffeine; Cross-Sectional Studies; Demography; Feeding Behavior; Female; Fol

2006
Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study.
    Human psychopharmacology, 2008, Volume: 23, Issue:4

    Topics: Adult; Aged; Antipsychotic Agents; Caffeine; Chromatography, High Pressure Liquid; Coffee; Cotinine;

2008
Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia.
    The Journal of nervous and mental disease, 1995, Volume: 183, Issue:9

    Topics: Adult; Alcoholism; Antipsychotic Agents; Caffeine; Female; Humans; Male; Marijuana Abuse; Middle Age

1995
Reduction of comorbid substance abuse with clozapine.
    The American journal of psychiatry, 1995, Volume: 152, Issue:6

    Topics: Alcohol Drinking; Caffeine; Clozapine; Comorbidity; Diagnosis, Dual (Psychiatry); Ethanol; Humans; S

1995
Current cannabis use and tardive dyskinesia.
    Schizophrenia research, 1993, Volume: 11, Issue:1

    Topics: Adult; Alcoholism; Antipsychotic Agents; Caffeine; Dyskinesia, Drug-Induced; Female; Humans; Male; M

1993
Interaction between caffeine and clozapine.
    Journal of clinical psychopharmacology, 1994, Volume: 14, Issue:4

    Topics: Adult; Caffeine; Clozapine; Coffee; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hum

1994
Temperament and substance abuse in schizophrenia: is there a relationship?
    The Journal of nervous and mental disease, 1997, Volume: 185, Issue:5

    Topics: Adolescent; Adult; Alcoholism; Caffeine; Coffee; Comorbidity; Exploratory Behavior; Humans; Male; Ma

1997
Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients.
    Journal of clinical psychopharmacology, 1998, Volume: 18, Issue:4

    Topics: Adult; Antipsychotic Agents; Biological Availability; Biotransformation; Caffeine; Chromatography, H

1998
Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism.
    Clinical pharmacology and therapeutics, 1999, Volume: 66, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Antipsychotic Agents; Caffeine; Case-Control Studies; Centr

1999
An animal model of nicotinic-acid-induced vasodilation: effect of haloperidol, caffeine and nicotine upon nicotinic acid response.
    Schizophrenia research, 2001, Jul-01, Volume: 50, Issue:3

    Topics: Animals; Antipsychotic Agents; Brain; Caffeine; Cerebrovascular Circulation; Disease Models, Animal;

2001
Reduced PGE1 stimulated 3H-cAMP accumulation in platelets from schizophrenics.
    Life sciences, 1978, Nov-13, Volume: 23, Issue:20

    Topics: Acute Disease; Adult; Blood Platelets; Caffeine; Chronic Disease; Cyclic AMP; Humans; In Vitro Techn

1978
Caffeine and schizophrenia.
    The Journal of clinical psychiatry, 1978, Volume: 39, Issue:9

    Topics: Acute Disease; Adult; Caffeine; Coffee; Female; Humans; Male; Psychoses, Substance-Induced; Schizoph

1978
Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects.
    The American journal of psychiatry, 1992, Volume: 149, Issue:9

    Topics: Adult; Age Factors; Akathisia, Drug-Induced; Ambulatory Care; Analysis of Variance; Basal Ganglia Di

1992
Exploring the role of an endogenous caffeine-like substance in the pathogenesis of schizophrenia.
    Medical hypotheses, 1991, Volume: 36, Issue:2

    Topics: Brain; Caffeine; Female; gamma-Aminobutyric Acid; Humans; Pregnancy; Pregnancy Complications; Recept

1991
Response to "Effects of caffeine on behavior of schizophrenic inpatients".
    Schizophrenia bulletin, 1990, Volume: 16, Issue:3

    Topics: Antipsychotic Agents; Caffeine; Dose-Response Relationship, Drug; Humans; Schizophrenia; Schizophren

1990
Effects of caffeine on behavior of schizophrenic inpatients.
    Schizophrenia bulletin, 1989, Volume: 15, Issue:2

    Topics: Caffeine; Chronic Disease; Coffee; Humans; Psychiatric Department, Hospital; Psychiatric Status Rati

1989
Hyponatremic coma and elevated serum creatine phosphokinase following excessive caffeine intake.
    Psychiatric journal of the University of Ottawa : Revue de psychiatrie de l'Universite d'Ottawa, 1986, Volume: 11, Issue:2

    Topics: Adult; Caffeine; Coma; Creatine Kinase; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Schi

1986
Dexamethasone suppression test in severe schizophrenic illness: effects of plasma dexamethasone and caffeine levels.
    Acta psychiatrica Scandinavica, 1987, Volume: 75, Issue:6

    Topics: Adult; Caffeine; Dexamethasone; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male

1987
[Effect of caffeine on drug-induced parkinsonism and the caudal reaction of arrest (clinical and experimental study)].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1973, Volume: 73, Issue:5

    Topics: Animals; Caffeine; Cats; Dose-Response Relationship, Drug; Electric Stimulation; Female; Humans; Mal

1973
[Kulenkampf-Tarnow syndrome, problems of its pathogenesis and treatment].
    Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1968, Volume: 68, Issue:2

    Topics: Adolescent; Adult; Atropine; Brain Stem; Caffeine; Chlorpromazine; Ephedrine; Humans; Male; Masticat

1968